AbCellera Biologics Inc. announced its financial results for the first quarter of 2025, reporting total revenue of $4.2 million. The company experienced a net loss of $45.6 million, compared to a net loss of $40.6 million in the same period of 2024. Sales and marketing expenses decreased to $2.8 million from $3.4 million in Q1 2024, while general and administrative expenses were reduced to $16.2 million from $17.4 million in the previous year. The company reported having $633 million in total cash, cash equivalents, and marketable securities, with approximately $178 million in available non-dilutive government funding, culminating in a total available liquidity of around $810 million. Significantly, AbCellera highlighted the introduction of ABCL635, a potential first-in-class antibody targeting non-hormonal treatment of vasomotor symptoms associated with menopause. The company also announced reaching a cumulative total of 97 partner-initiated program starts with downstreams and 16 molecules having reached the clinic by the end of the quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.